9 Things to Know About Low-Dose Naltrexone for Menopause Pain, Inflammation, and Mood
The women who find their way to LDN have usually already tried a lot of things. They've been told their pain is stress, their inflammation is just 'getting older,' and their mood swings are something to manage with breathing exercises. Discovering that there's a decades-old generic drug with a genuinely interesting mechanism — one their doctor may never have mentioned — tends to produce equal parts relief and frustration. Both reactions make complete sense.
Learn more about Rose →Naltrexone at full dose blocks opioid receptors — but at low dose, it does something entirely different
Standard naltrexone (50mg) is FDA-approved to treat opioid and alcohol dependence by fully occupying opioid receptors and blocking their activation. Low-dose naltrexone (LDN), typically 1.5–4.5mg taken at night, works through a paradoxical rebound mechanism: the brief, partial blockade triggers the body to upregulate its own endorphin production and sensitize opioid receptors. This rebound effect — not receptor blockade — is what drives LDN's proposed benefits for pain, immune function, and mood.
LDN appears to calm microglial overactivation — which matters enormously in perimenopause
Microglia are the brain's resident immune cells, and when chronically activated they drive neuroinflammation, amplify pain signals, and contribute to mood dysregulation. Estrogen normally keeps microglial activity in check, so as estrogen fluctuates and declines during perimenopause, microglial overactivation becomes a real physiological problem. LDN has been shown in preclinical and some human studies to act as a microglial inhibitor via toll-like receptor 4 (TLR4) antagonism — a mechanism entirely separate from its opioid receptor effects.
Central sensitization — not just tissue damage — explains why perimenopausal pain is so hard to treat
Central sensitization is a state in which the central nervous system becomes amplified in its pain response, generating or magnifying pain signals even without ongoing tissue injury. Perimenopause is increasingly recognized as a period of heightened central sensitization risk, partly because estrogen modulates pain-processing pathways in the spinal cord and brain. LDN's combination of endorphin upregulation and microglial suppression makes it one of the few agents specifically targeting this central mechanism rather than peripheral inflammation alone.
There is growing clinical interest in LDN for fibromyalgia and other central pain conditions that cluster in midlife women
A small but well-designed Stanford RCT found that LDN (4.5mg) significantly reduced fibromyalgia pain scores compared to placebo, with participants reporting roughly 30% greater pain reduction on LDN. Fibromyalgia disproportionately affects women in their 40s and 50s, and many women receive a fibromyalgia diagnosis for the first time during perimenopause — often without any discussion of the hormonal context. While LDN is not approved for fibromyalgia, the mechanistic overlap with central sensitization gives this line of research genuine credibility.
LDN has documented immune-modulating effects relevant to autoimmune flares that often worsen in perimenopause
Several autoimmune conditions — including Hashimoto's thyroiditis, rheumatoid arthritis, and lupus — are known to flare or first appear during perimenopause, likely because estrogen withdrawal disrupts immune tolerance. LDN has been studied in Crohn's disease, multiple sclerosis, and Hashimoto's, with observational data and small trials suggesting reductions in inflammatory markers and symptom burden. The proposed mechanism involves both TLR4 antagonism and endorphin-mediated modulation of T-regulatory cell activity, both of which influence autoimmune activity.
The mood effects of LDN are biologically plausible and reported consistently in clinical practice, even if RCT data is thin
Beta-endorphin — the endogenous opioid whose production LDN is thought to amplify — plays a direct role in mood regulation, emotional resilience, and the blunting of stress responses. Perimenopausal women often experience a drop in baseline endorphin tone as estrogen declines, which contributes to irritability, emotional reactivity, and low-grade anhedonia that doesn't always respond to SSRIs. Clinicians using LDN in perimenopausal patients frequently report improvements in mood stability and emotional bandwidth, though controlled trial data specifically in this population remains limited.
LDN's side effect profile is generally mild, but sleep disruption and vivid dreams are the most commonly reported issues
Because LDN is typically taken at night to coincide with the natural peak of endorphin production, vivid dreams and transient sleep disturbance are the most frequently cited side effects — affecting roughly 30–40% of new users, though most resolve within two to four weeks. Nausea and mild headache are occasionally reported in the first week of use. Unlike many medications used for pain or mood in midlife, LDN carries no addiction potential, no hormonal activity, and no significant drug interactions at low doses for most people.
LDN requires a prescription and must be compounded — which means navigating a system not set up for it
Because naltrexone is only FDA-approved in 50mg tablets, the low-dose formulations used clinically (typically 1.5–4.5mg) must be prepared by a compounding pharmacy, and most standard pharmacies do not carry them. This means women need a prescriber willing to write an off-label prescription and a relationship with a compounding pharmacy — two hurdles that can feel significant in a healthcare system already underserving perimenopausal women. Cost is typically modest (often $30–60/month without insurance), but insurance coverage is inconsistent because of the off-label status.
LDN is not a replacement for HRT in perimenopause — but it may be a useful complement for women who can't or won't use hormones
Hormone replacement therapy remains the most evidence-backed intervention for the hormonal root causes of perimenopausal symptoms, and LDN does not address estrogen or progesterone deficiency directly. However, for women with contraindications to HRT, or those who experience persistent inflammation, pain, or mood symptoms even on HRT, LDN addresses a different layer of the biology — the neuroinflammatory and central sensitization component — that hormones alone don't fully resolve. Some clinicians are beginning to use both in combination, though formal trials of this approach don't yet exist.
Want to go deeper?
Rose covers every symptom, supplement, and condition in full detail — evidence-graded and agenda-free.
Rose is a free, evidence-based reference built for women navigating perimenopause and menopause. No ads. No products to sell. No agenda. Just honest answers — because every woman in this season deserves a trusted friend who has done the research.